Thermo Fisher Scientific Inc. - Q1 2009 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Thermo Fisher Scientific Inc. for the three-month period ended March 28, 2009. The company operates in two primary segments: Analytical Technologies and Laboratory Products and Services. The reporting period reflects the impact of a global economic downturn, which significantly reduced demand for capital equipment and laboratory products.
Key Financial Metrics
| Metric (in millions) | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenues | $2,255.1 | $2,554.0 |
| Operating Income | $190.1 | $290.4 |
| Operating Margin | 8.4% | 11.4% |
| Net Income | $148.9 | $229.7 |
| Diluted EPS | $0.35 | $0.53 |
| Cash from Operations | $358.7 | $243.0 |
| Cash & Equivalents (End of Period) | $1,561.1 | $734.0 |
| Total Debt | $2,026.7 | $2,018.0 |
Note: Total Debt includes Short-term obligations ($15.6M) and Long-term Obligations ($2,011.1M). Approximately $0.9 billion of debt is convertible.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by $299 million (12%) year-over-year. Organic revenue declined 7% due to decreased demand, particularly in equipment sales, partially offset by price increases. Currency translation had an unfavorable impact of $133 million.
- Profitability Compression: Operating income fell 35% to $190.1 million. This was driven by lower profitability at existing businesses and an $8.7 million increase in restructuring and other costs (net) to $13.6 million.
- Segment Performance:
- Analytical Technologies: Revenue down 14% ($938.8M); Operating income down 24% ($173.5M). Weakness in industrial markets for environmental and process control instruments was noted.
- Laboratory Products and Services: Revenue down 9% ($1,423.0M); Operating income down 20% ($175.5M). Weakness in laboratory equipment sales and a decrease in sales of products purchased from a specific supplier contributed to the decline.
- Cash Flow Improvement: Despite lower earnings, cash provided by operating activities increased 48% to $358.7 million, primarily due to a decrease in accounts receivable and a tax refund receipt.
Guidance, Outlook, and Risks
- Restructuring Outlook: As of May 1, 2009, the company identified additional restructuring actions expected to result in approximately $22 million in charges for the remainder of 2009. Annual cost savings from actions initiated in late 2008 and Q1 2009 are expected to total approximately $50 million.
- Tax Rate: The effective tax rate for Q1 2009 was 10.9%. Management expects the full-year 2009 tax rate to be approximately 10% - 12%.
- Capital Expenditures: Expected to approximate $230 - $250 million for the full year 2009.
- Acquisitions: On April 30, 2009 (post-period), the company completed the acquisition of Biolab for approximately $120 million USD.
- Risks:
- Economic Downturn: Continued global recession could lead to further order cancellations, delays, and excess inventory.
- Goodwill Impairment: With $8.66 billion in goodwill and $6.23 billion in acquisition-related intangibles, a material decrease in future profitability could trigger impairment charges.
- Convertible Debt: Approximately $295 million of convertible debt was convertible as of May 1, 2009. The company intends to use its $951 million revolving credit facility to fund cash principal payments if conversion occurs.
- Litigation: Ongoing patent infringement litigation regarding mass spectrometer systems could have a material adverse effect if the outcome is unfavorable.
Investor Verification Checklist
- Restructuring Execution: Verify the timing and actual cost of the projected $22 million in additional restructuring charges and the realization of the $50 million in annual cost savings.
- Convertible Debt Conversion: Monitor the stock price relative to conversion prices ($23.73 - $40.20) to assess the risk of early conversion and the potential strain on liquidity.
- Goodwill Valuation: Assess the sensitivity of the $14.9 billion in goodwill and intangible assets to further declines in segment operating income.
- Supplier Concentration: Review the impact of the revised agreement with the healthcare market channel supplier, which is expected to reduce revenues by approximately $63 million annually compared to 2008.
- Working Capital Trends: Confirm if the strong cash collection from accounts receivable in Q1 2009 is sustainable or a one-time benefit of lower sales volume.